Trial Profile

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FDA-022-BB05 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Male breast cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Most Recent Events

16 May 2024 Planned End Date changed from 1 May 2025 to 1 Nov 2025.
16 May 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Sep 2025.
16 May 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com